Home / Medical Devices / Actinic Keratosis Market By Treatments (Destructive Treatment, Photodynamic Therapy, Topical Medications, Chemical Peels And Dermabrasion) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Actinic Keratosis Market By Treatments (Destructive Treatment, Photodynamic Therapy, Topical Medications, Chemical Peels And Dermabrasion) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: Jul 2016 | Report Code: 58011-07-16

Actinic keratosis (AK) or solar keratosis are keratotic papules, macules and plaques arising from intraepidermal proliferation of keratinocytes due to exposure to ultraviolet radiation. Although AKs to squamous cell carcinoma progression is rare, AKs still pose a concern because majority of cutaneous squamous cell carcinoma result from pre-existing AKs. Due to this, clinicians recommend routine treatment of AKs. This report studies the current and future prospects of the global actinic keratosis treatment market.

For the purpose of this report, the global actinic keratosis market is studied in terms of treatment type and geographical distribution. Based on treatment type, this market is segmented into destructive treatment (liquid nitrogen cryotherapy, surgical therapy), photodynamic therapy (5-aminolevulinic acid, methyl aminolevulinate), topical medications (5-fluorouracil, imiquimod, ingenolmebutate, diclofenac sodium), and chemical peels and dermabrasion. Market size and forecast for each considered segment is provided for the period 2014-2022 (USD Mn) along with respective CAGR (value %) for the forecast duration 2016-2022 are provided in the report.

Geographically the global actinic keratosis market is studied for the following regional and country-level markets:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Spain
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa

Each country level market (and Middle East and Africa, and Latin America markets) thus covered in the report include cumulative market size and forecast of destructive treatment, photodynamic therapy, topical medications, and chemical peels and others. In addition, since photodynamic therapy has opened further avenues for effective AK treatment, this section also presents exclusive market size and forecast for 5-aminolevulinic acid (ALA) and methyl aminolevulinate (MAL) segments for the country-level and Middle East and Africa, and Latin America markets. The market size and forecast, along with growth rates are provided for the considered periods 2014-2022 and 2016-2022 respectively.

Along with quantitative presentations, this report also includes analysis of market environment factors such as drivers, restraints and opportunities that determine the overall trends in actinic keratosis market. Competition assessment tools such as attractive investment proposition, market competitive analysis by key players and market inclination insights are also incorporated in this study. This report concludes with profiling of major companies active in development,manufacturing and sale of AK treatments. Such profiling is done based on business description, financial health, product portfolio and news coverage of such considered players.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Actinic Keratosis Market Revenue, by Treatment, 2015, (US$ Mn)
2.2 Global Actinic Keratosis Market Revenue, by Geography, 2015, (USD Million)

Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 High Prevalence of Actinic Keratosis and Subsequent Risk of Developing Malignancies
3.3.2 Restraints
3.3.2.1 Non-adherence to Treatments
3.3.3 Market Opportunities
3.3.3.1 Lucrative future for Light-based Treatments
3.4 Attractive Investment Proposition
3.5 Market Competition Assessment Key Players: Global Actinic Keratosis Market

Chapter 4 Global Actinic Keratosis Market, by Treatments
4.1 Preface
4.2 Destructive Treatment
4.2.1 Liquid Nitrogen Cryotherapy
4.2.2 Surgical Therapy
4.3 Photodynamic Therapy
4.3.1 5-aminolevulinic acid (ALA)
4.3.2 Methyl Aminolevulinate (MAL)
4.4 Topical Medications
4.4.1 5-fluorouracil [5-FU]
4.4.2 Imiquimod
4.4.3 Ingenol Mebutate
4.4.4 Diclofenac Sodium
4.5 Chemical Peels and Dermabrasion

Chapter 5 Global Actinic Keratosis Market, by Geography
5.1 Preface
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Tolmar Pharmaceuticals, Inc.
6.1.1 Tolmar Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.2 DUSA Pharmaceuticals, Inc. (Sun Pharma)
6.2.1 DUSA Pharmaceuticals, Inc. (Sun Pharma): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.3 Valeant Pharmaceuticals International, Inc.
6.3.1 Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.4 Aqua Pharmaceuticals, LLC
6.4.1 Aqua Pharmaceuticals, LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.5 Galderma S.A.
6.5.1 Galderma S.A.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.6 Perrigo Company plc,
6.6.1 Perrigo Company plc,: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.7 Apotex, Inc.
6.7.1 Apotex, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.8 LEO Laboratories Ltd. (LEO Pharma A/S)
6.8.1 LEO Laboratories Ltd. (LEO Pharma A/S): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Table :

TABLE 1 Global Actinic Keratosis Market, by Treatment, 2013-2022 (USD Million)
TABLE 2 Global Destructive Treatment Market, by Type, 2014-2022 (USD Million)
TABLE 3 Global Photodynamic Therapy Market, by Products, 2014-2022 (USD Million)
TABLE 4 Global Topical Medications Market, by Products, 2014-2022 (USD Million)
TABLE 5 Global Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 6 North America Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 7 U.S. Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 8 U.S. Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 9 Canada Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 10 Canada Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 11 Europe Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 12 U.K. Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 13 U.K. Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 14 Germany Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 15 Germany Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 16 France Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 17 France Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 18 Spain Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 19 Spain Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 20 Italy Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 21 Italy Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 22 Rest of Europe Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 23 Rest of Europe Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 24 Asia Pacific Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 25 Japan Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 26 Japan Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 27 China Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 28 China Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 29 Australia Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 30 Australia Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 31 Rest of APAC Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 32 Rest of APAC Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 33 Latin America Actinic Keratosis Market, by Treatment, 2015 – 2022 (USD Mn)
TABLE 34 Latin America Photodynamic Therapy Market, by Type, 2015 – 2022 (USD Mn)
TABLE 35 Middle East and Africa Actinic Keratosis Market, by Treatment, 2015 – 2022 (USD Mn)
TABLE 36 Middle East and Africa Photodynamic Therapy Market, by Type, 2015 – 2022 (USD Mn)
TABLE 37 Tolmar Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 38 DUSA Pharmaceuticals, Inc. (Sun Pharma): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 39 Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 40 Aqua Pharmaceuticals,LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 41 Galderma S.A.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 42 Perrigo Company plc,: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 43 Apotex, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 44 LEO Laboratories Ltd. (LEO Pharma A/S): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Figure :

FIG. 1 Actinic Keratosis Treatment Market: Research Methodology
FIG. 2 Global Actinic Keratosis Market Revenue, by Treatment, 2015 (USD Mn)
FIG. 3 Global Actinic Keratosis Market Revenue, by Geography, 2015 (Value %)
FIG. 4 Risk Factors Associated with Development of Actinic Keratosis
FIG. 5 Attractive Investment Proposition: Global Actinic Keratosis Market
FIG. 6 Top 3 Countries: Global Destructive Treatment Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)
FIG. 7 Liquid Nitrogen Cryotherapy Market, 2014 – 2022 (US$ Mn)
FIG. 8 Surgical Therapies Market, 2014 – 2022 (US$ Mn)
FIG. 9 Top 3 Countries: Global Photodynamic Therapy Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)
FIG. 10 5-aminolevulinic acid (ALA) Market, 2014 – 2022 (US$ Mn)
FIG. 11 Methyl aminolevulinate (MAL)Market, 2014 – 2022 (US$ Mn)
FIG. 12 Top 3 Countries: Global Topical Medications Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)
FIG. 13 5-fluorouracil (5-FU) Market, 2014 – 2022 (US$ Mn)
FIG. 14 Imiquimod Market, 2014 – 2022 (US$ Mn)
FIG. 15 Ingenol Mebutate Market, 2014 – 2022 (US$ Mn)
FIG. 16 Diclofenac Sodium Market, 2014 – 2022 (US$ Mn)
FIG. 17 Chemical Peels and Dermabrasion Market, 2014 – 2022 (US$ Mn)
FIG. 18 Top 3 Countries: Global Chemical Peels & Dermabrasion Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)

Based ontreatment types, the global actinic keratosis market categorized into:

  • Destructive  Treatment
    • Liquid Nitrogen Cryotherap
    • Surgical Therapy
  • Photodynamic Therapy
    • 5-aminolevulinic acid (ALA)
    • methyl aminolevulinate (MAL)
  • Topical Medications
    • 5-fluorouracil (5-FU)
    • Imiquimod
    • Ingenolmebutate
    • Diclofenac Sodium
  • Chemical Peel and Others

Actinic Keratosis Market

In 2015, destructive treatments accounted for the largest share in the overall actinic keratosis market. On the ground of their proven efficiency and cost effectiveness, cryotherapy and surgical methods are considered as gold standard for AKs treatment worldwide. Cryosurgery is the largest segment across all the available treatment methods and takes over 50% of the destructive treatments market. Laser treatment such as carbon dioxide and erbium:yttrium-aluminum-garnet laser are also being increasingly preferred by clinicians due to their effectiveness, and aesthetic appeal. Topical medications constitute prolonged treatment regimen and plays a key role in AK treatment; however, patient compliance is a key issue that holds back the growth of this segment. Yet, cheaper treatment costs favor the stability of this topical medicationsparticularly in middle- and low-income markets. Photodynamic therapy is the fastest growing segment through the forecast period due to growing demand for non-invasive treatments and aesthetic appeal of photodynamic therapy.

Based on geographical segmentation, the actinic keratosis market is studied for:

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • Latin America
  • Middle East and Africa

Actinic Keratosis Market

North America is the largest market for actinic keratosis treatments due to growing AK prevalence and high public awareness about prevention and management of skin cancer. U.S. holds the largest share in the global actinic keratosis market in 2015 owing to high prevalence of AK in the country, supplemented by favorable reimbursements for AK treatment. Asia-Pacific is the fastest progressing regional market for AK treatments Australia has the largest prevalence of actinic keratosis at a range between 40% to 50% in adults. Growing awareness in potential population group, improving healthcare infrastructure and healthcare expenditure are the key drivers of this market. Japan is also actively progressing market for the actinic keratosis treatment in terms of revenue. Japan as a market is probably 2-3 years behind Europe in terms of development actinic keratosis.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients